The advancement of “smart” drug development reaches far back in the drug development cycle, starting at the R&D phase and moving through the pipeline through to clinical studies. Data gathering and deep data analysis in the preclinical stages of development are growing increasingly crucial as the biopharmaceutical industry strategizes ways to better decrease costs while speeding up timelines to market. Here, a closer look at smart tools highlights how they support enhanced and intelligent data gathering as well as analysis in drug discovery and preclinical studies.
To further explore the intricacies of smart tool utilization in preclinical studies and early phase drug development in general, BioPharm International spoke with Jijie Gu, PhD, chief scientific officer and executive vice-president of WuXi Biologics. To read the full article, please visit: https://www.biopharminternational.com/view/the-smart-benefit-of-digital-systems-in-preclinical-studies.